A share price of Ascendis Pharma A/S ADR [ASND] is currently trading at $156.19, up 8.41%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ASND shares have gain 30.71% over the last week, with a monthly amount glided 18.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on January 07, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $196. Previously, Oppenheimer upgraded its rating to Outperform on September 05, 2024, and kept the price target unchanged to $180. On June 25, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $175 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $200 on May 31, 2024. Jefferies initiated its recommendation with a Buy and recommended $150 as its price target on December 20, 2023. In a note dated April 05, 2023, Oppenheimer downgraded an Perform rating on this stock.
Ascendis Pharma A/S ADR experienced fluctuations in its stock price throughout the past year between $111.09 and $161.00. Currently, Wall Street analysts expect the stock to reach $208.86 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $156.19 at the most recent close of the market. An investor can expect a potential return of 33.72% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Trailing Twelve Months sales for Ascendis Pharma A/S ADR [NASDAQ:ASND] were 391.88M which represents 25.27% growth. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.77%, Pretax Profit Margin comes in at -1.03%, and Net Profit Margin reading is -1.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 1.98 and Total Capital is -1.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -8.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 148.34 points at the first support level, and at 140.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 160.71, and for the 2nd resistance point, it is at 165.22.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ascendis Pharma A/S ADR [NASDAQ:ASND] is 1.17. Further, the Quick Ratio stands at 0.84, while the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 23.85.
Transactions by insiders
Recent insider trading involved JENSEN FLEMMING STEEN, Officer, that happened on Feb 18 ’25 when 10000.0 shares were purchased. Officer, SINGEL STINA completed a deal on Dec 10 ’24 to buy 2119.0 shares. Meanwhile, Officer JENSEN MICHAEL WOLFF bought 2119.0 shares on Dec 10 ’24.
